DxS, Epigenomics Exercise Cross-Licensing Options for IVD Development

The two companies have cross-licensed "certain technologies," enabling both firms to develop IVD products based on DNA methylation that use DxS' Scorpions technology.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.